Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q113943> ?p ?o }
Showing triples 1 to 19 of
19
with 100 triples per page.
- Q113943 subject Q7066600.
- Q113943 subject Q7329501.
- Q113943 subject Q8388423.
- Q113943 abstract "Repoxygen is the tradename for a type of gene therapy that induces controlled release of erythropoietin (EPO) in response to low oxygen concentration. It has been developed by Oxford Biomedica to treat anaemia. It has been developed in mice, is still in preclinical development and has not been extensively tested in humans.It is constructed as a viral gene delivery vector carrying the human EPO gene under the control of a so-called "hypoxia control element" (“HRE”). The HRE is claimed to sense low oxygen concentrations and to switch a gene on in response. Repoxygen is designed to be delivered by injection into muscle and therefore to induce syntheses of EPO in the muscle tissue. Normally, EPO is synthesized in the liver and kidneys. It leads to increased production of red blood cells.Use of recombinate EPO DNA in mice has shown protective effects for epithelial cells and is being investigated as a prophylatic treatment for lung tissue injury.Excess EPO, the signalling hormone for more red blood cell production (increased erythrocytes), can lead to erythrocytosis—a condition of too many red blood cells. Erythrocytosis makes the blood thicker and more viscous, making pooling and clotting more likely, and represents an increased stress on the heart (due to the thicker blood). Erythrocytosis is potentially fatal, especially in endurance athletes who are frequently dehydrated during long events.".
- Q113943 wikiPageExternalLink Finding_the_golden_genes.
- Q113943 wikiPageWikiLink Q14852026.
- Q113943 wikiPageWikiLink Q213901.
- Q113943 wikiPageWikiLink Q2298489.
- Q113943 wikiPageWikiLink Q37187.
- Q113943 wikiPageWikiLink Q5445.
- Q113943 wikiPageWikiLink Q7066600.
- Q113943 wikiPageWikiLink Q7329501.
- Q113943 wikiPageWikiLink Q749394.
- Q113943 wikiPageWikiLink Q83310.
- Q113943 wikiPageWikiLink Q8388423.
- Q113943 wikiPageWikiLink Q9368.
- Q113943 wikiPageWikiLink Q9377.
- Q113943 comment "Repoxygen is the tradename for a type of gene therapy that induces controlled release of erythropoietin (EPO) in response to low oxygen concentration. It has been developed by Oxford Biomedica to treat anaemia. It has been developed in mice, is still in preclinical development and has not been extensively tested in humans.It is constructed as a viral gene delivery vector carrying the human EPO gene under the control of a so-called "hypoxia control element" (“HRE”).".
- Q113943 label "Repoxygen".